DEA Defends HHC Ban in Fourth Circuit Court Fight

August 15, 2026

Photo by Sasun Bughdaryan via Unsplash.

The DEA filed its latest volley in a fight over lab-modified hemp compounds on August 12, 2026, telling the Fourth Circuit Court of Appeals that a company called Bluestar Operations has no business bringing its challenge in the first place -- and that even if it did, the case would fall apart on the merits. At the center of the dispute is hexahydrocannabinol, better known as HHC, a cannabinoid that doesn't occur in nature in any meaningful quantity but has become a fixture on smoke shop shelves and gas station counters across the country over the past few years.

The legal question sounds narrow but isn't: does HHC count as legal hemp under the 2018 Farm Bill, or is it a controlled substance the DEA has every right to ban? That question is now pending in two different circuit courts at once, and those courts have a track record of disagreeing with each other on strikingly similar cannabinoids. Whatever the Fourth Circuit decides -- and whatever the Ninth Circuit decides in its own parallel case -- stands to determine the legal fate of a massive segment of the intoxicating hemp market that has grown up in the gray zone left by federal hemp law.

How We Got Here: The May 4 Scheduling Order

Photo by Elsa Olofsson via Pexels.

The current fight traces back to a scheduling order the DEA issued on May 4, 2026, which put HHC squarely into Schedule I of the Controlled Substances Act. The agency didn't frame this as a new policy so much as a clarification of what it says Congress meant all along. Its position: lawmakers who wrote the 2018 Farm Bill were legalizing hemp and its naturally occurring cannabinoids, not opening the door to lab-modified molecules that happen to start with a hemp-derived precursor.

The order itself is blunt about where the agency draws that line. DEA's language holds that only tetrahydrocannabinols in or derived from the cannabis plant -- not synthetic ones -- are excluded from control, a distinction that puts the entire manufacturing process for HHC on the wrong side of federal law as the agency sees it.

That distinction matters because of how HHC actually gets made. It does show up in trace, naturally occurring amounts in the cannabis plant, but nobody is extracting commercial quantities of it that way -- it wouldn't be commercially viable. Instead, manufacturers typically start with CBD and run it through a hydrogenation process, essentially the same basic chemistry used to turn liquid vegetable oil into solid margarine, adding hydrogen atoms to alter the molecule's structure. The resulting HHC oil then gets applied to low-THC hemp flower or infused into vapes, edibles, and tinctures. Users and retailers describe the psychoactive effects as comparable to conventional THC, which is precisely why the product built a market in states where THC-heavy cannabis remains restricted or illegal.

Hemp Companies Sue: Two Circuits, Two Precedents

Photo by Elsa Olofsson via Unsplash.

Hemp companies didn't sit on the DEA's scheduling order. On June 2, 2026, they went to court, and notably, they didn't file one unified case -- they filed two, in two different circuits, each betting on favorable precedent already on the books.

Bluestar Operations took its challenge to the Fourth Circuit, a court that previously ruled THC-O-acetate -- another lab-altered cannabinoid -- is federally legal despite DEA's objections to that compound as well. That precedent gives Bluestar a real foothold: if the same court already decided synthetic modification of a hemp-derived molecule doesn't automatically strip it of legal status, there's an argument HHC should get similar treatment.

A separate case landed in the Ninth Circuit, which has its own favorable history for the hemp side. That court previously held the 2018 Farm Bill freed a wide range of cannabis-derived molecules from federal restriction, including delta-8 THC, a compound that has followed almost the identical commercial path as HHC -- synthesized from CBD, sold as a lower-shelf alternative to traditional THC products, and litigated repeatedly by an industry trying to keep it legal.

Having two circuits actively considering nearly identical legal questions raises the odds of an outright split, which carries its own consequences down the line. The hemp companies' shared legal argument leans on the statutory text itself: they say Congress used deliberately broad language in the Farm Bill covering extraction, refinement, conversion, hydrogenation, and distillation, methods that describe standard industry processing rather than some illicit synthetic loophole.

DEA's Standing and Merits Arguments in the New Brief

Photo by Andy Feliciotti via Unsplash.

DEA's August 12 brief takes a two-track approach that's common in federal litigation but still worth unpacking. First, the agency argues Bluestar Operations lacks standing to bring the challenge at all -- a procedural argument that, if it succeeds, would let the court avoid ruling on HHC's legality altogether. Second, and only if the standing argument fails, DEA argues the challenge loses on the merits regardless.

On the merits, the agency's framing is pointed: it calls HHC a synthetic hallucinogenic drug that has sat in Schedule I for decades under the Controlled Substances Act, long before the current wave of hemp-derived products existed. The core legal theory underneath that claim is that the Farm Bill's 0.3% delta-9 THC threshold, the dividing line between legal hemp and illegal marijuana, was only ever meant to cover cannabinoids occurring naturally in the plant, not compounds engineered afterward through chemical processes.

This isn't DEA's first move in the case. Back in late June, the agency also opposed the companies' request for a stay pending review, arguing petitioners failed to meet any of the required factors courts use to decide whether to pause enforcement during litigation -- likelihood of success, irreparable harm, and so on. That opposition means HHC's Schedule I status has stayed in effect this whole time, litigation notwithstanding.

Petitioners are pushing back with the major questions doctrine, the increasingly influential legal principle that agencies need clear, explicit authorization from Congress before making decisions of major economic and political significance. Given how large the intoxicating hemp market has grown, the companies argue DEA can't simply reinterpret its way into banning a huge product category without Congress weighing in directly.

Why This Case Matters Beyond HHC

Photo by freestocks.org via Pexels.

HHC is just the test case -- the reasoning a court adopts here won't stay contained to one molecule. Delta-8, delta-10, THC-O, and whatever the next lab-modified cannabinoid turns out to be all rely on the same basic legal argument: that they're derived from legal hemp through processes the Farm Bill's broad language covers. A ruling that draws a hard line between natural and synthetic cannabinoids would put all of them at risk, not just HHC.

The circuit dynamics make this especially consequential. If DEA wins in the Fourth Circuit while the hemp industry wins in the Ninth Circuit, that's a textbook circuit split, and circuit splits are exactly the kind of conflict the Supreme Court tends to step in to resolve. Given how much money is tied up in the hemp-derived cannabinoid market nationally, a split outcome would likely accelerate a push toward the high court rather than leaving the disagreement to simmer.

In the meantime, the ground-level reality is messy. State laws on HHC and similar synthetic cannabinoids already vary enormously -- some states have banned them outright, others regulate them like other hemp products, and others haven't addressed them with any clarity at all. Because DEA opposed a stay, retailers and manufacturers currently selling or shipping HHC products are doing so while the federal scheduling order remains technically in force, which means real enforcement exposure exists right now, not just after some future ruling.

Anyone buying, selling, or shipping HHC products should check current state and local law before doing so. This is a fast-moving area of law, and what's legal in one state can be a controlled substance the moment a product crosses a border.

Watching the briefs pile up, it's clear the Fourth Circuit's eventual ruling won't turn much on chemistry -- everyone agrees on how HHC is made. It will turn on how far judges think the Farm Bill's language was ever meant to stretch, whether Congress's words about extraction and conversion were written broadly enough to cover a molecule that barely exists in nature and mostly gets built in a lab from CBD.

If the Fourth Circuit sides with DEA while the Ninth Circuit's parallel case breaks the other way, that split makes Supreme Court involvement look less like a possibility and more like an eventuality. Federal courts don't love leaving contradictory readings of the same statute standing indefinitely, especially once real money and criminal exposure are riding on the answer.

None of that resolves anything for businesses operating right now. Until a ruling lands, HHC's legal status stays a patchwork, shaped by which state you're in and which circuit's precedent happens to apply, with genuine enforcement risk sitting underneath the whole market while the litigation plays out.